Helix to raise $16.9 million through private placement

Guest Contributor
December 21, 2007

Helix Biopharma Corp, Aurora ON, has launched a private placement that is expected to yield $16.9 million upon closing later this month. The funds will be used primarily to fund R&D for products aimed at the prevention and treatment of cancer. The private placement coincides with the firm's latest quarterly financial statements and follows major changes within the executive. The joint role of CEO and president, held by Dr Donald Segal, will be separated. Segal remains CEO and Dr John Docherty (previously VP corporate development) becomes president. Jerome McElroy has resigned as chairman and director of the company. Helix's lead compound is Topical Interferon Alpha 2b....


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.